Diabetic Nephropathy. Glomerular disorders in diabetes mellitus
Conditions
Interventions
Intervention 1: 800 mg lipoic acid placebo (as 2 capsules) and 80 mg pyridoxine placebo (as 2 tablets) daily for 12 weeks. Intervention 2: 800 mg lipoic acid (as 2 capsules)and 80 mg pyridoxine (as 2
Placebo
Treatment - Drugs
800 mg lipoic acid placebo (as 2 capsules) and 80 mg pyridoxine placebo (as 2 tablets) daily for 12 weeks
800 mg lipoic acid (as 2 capsules)and 80 mg pyridoxine (as 2 tablets) daily for 12 weeks
Sponsors
National Nutrition and Food Technology Research Institute
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Presence of Diabetic Nephropathy Exclusion Criteria: Chronic kidney disease, Infections, Inflammatory diseases, Receiving anti-inflammatory drugs, Vitamins B6, E, C, and Lipoic acid supplement
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Microalbuminuria. Timepoint: Baseline and Week 12. Method of measurement: ELISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hb A1c. Timepoint: Baseline and Week 12. Method of measurement: Ion Exchange Chromatography.;Serum MDA, NO, Glucose. Timepoint: Baseline and Week12. Method of measurement: Colorimetry.;Systolic and diastolic blood pressure. Timepoint: Baseline and Week 12. Method of measurement: Mercury Sphygmomanometer.;Serum pentosidine, carboxymethyl lysine, hs-CRP, IL-6, sICAM-1, sVCAM-1, sE-selectin, Endothelin-1. Timepoint: Baseline and Week12. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Hadi Tabibi
Department of Human Nutrition, Faculty of Nutrition Sciences and Food Technology, National Nutrition
Outcome results
None listed